Amprenavir

CHEMBL116 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
505.6 g/mol
LogP
2.9
Phase
4

A protease inhibitor that blocks an enzyme HIV needs to produce infectious new virus particles, reducing the amount of virus in the blood. It was an early option in combination HIV therapy, though it has largely been replaced by newer agents.

Moleküler Ağırlık

505,6000 g/mol

LogP

2,90

TPSA

140,00 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1

InChI

InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1

Molecular Formula

C25H35N3O6S

HBD / HBA

3 / 8

Döndürülebilir Bağlar

12

Ağır Atomlar

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A protease inhibitor that blocks an enzyme HIV needs to produce infectious new virus particles, reducing the amount of virus in the blood. It was an early option in combination HIV therapy, though it has largely been replaced by newer agents.

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Yes, Amprenavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL116. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 65016. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.